ReviewWorld journal of diabetes2025
Mechanisms behind the anti-diabetic and anti-obesity effects of seaweeds or macroalgae and their bioactive compounds.
Review in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Phytochemical Analysis, Antioxidant Activity, and Inhibition of Digestive Enzymes ofMolecules (Basel, Switzerland) · 2026Article
- Multi-Omics-Guided Discovery ofMarine drugs · 2026Article
- Research Progress on Polyphenols and Polysaccharides from Marine Seaweeds: Promising Diabetes Management Natural Products.Marine drugs · 2026Review
- Brown Seaweeds and Their Bioactive Compounds in Type 2 Diabetes: Mechanisms Underlying Metabolic Regulation.International journal of molecular sciences · 2026Review
- Edible Marine Red AlgaFoods (Basel, Switzerland) · 2026Article
- Integrative Metabolomics and Systems Pharmacology Reveal PPARγ-Centered Antidiabetic Mechanisms ofMarine drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and diabetes have become global health crises, with rising prevalence and a strong association with various chronic diseases such as cardiovascular disease, stroke, and certain cancers. These conditions contribute to significant morbidity and mortality, highlighting the urgent need for effective therapeutic interventions. Marine products, including fish oils and marine plants, have been increasingly recognized for their potential in mitigating these diseases. Among these, seaweed stands out due to their diverse bioactive compounds and promising therapeutic effects. This comprehensive review explores the mechanisms of action through which seaweeds, and their compounds exert anti-diabetic and anti-obesity effects, including the regulation of adipogenesis, appetite control, modulation of gut microbiota, enhancement of insulin sensitivity, and reduction of inflammation, oxidative stress, and β-cell dysfunction. Despite the promising potential, challenges such as variability of bioactive compounds and low bioavailability remain there. Advances in bioactive delivery systems and along with large-scale clinical trials, are crucial for optimizing the therapeutic use of bioactive compounds from seaweeds. Future research should also explore synergistic strategies combining seaweed compounds with other bioactive substances. Overall, seaweed offers a promising foundation for developing functional foods and nutraceuticals aimed at promoting long-term metabolic health, providing an innovative approach to addressing obesity and diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.